Bio-Bridge Science’s Colon Cancer vaccine is designed to treat CEA+ colon cancer. Our colon cancer vaccine will be an oral vaccine. This vaccine induces intestinal (colonic) cytotoxic T lymphocytes and antibodies against CEA+ tumors. This vaccine is still in laboratory animal experimental stage. Our subsidiary, Bio-Bridge Science (Beijing), will produce the colon cancer vaccine in our Research and Development facility in Beijing and conduct pre-clinical testing on our colon cancer vaccine in 2010. Bio-Bridge Science (Beijing) will apply to China's State Food and Drug Administration for approval to conduct clinical trials on the colon cancer vaccine after the pre-clinical testing is completed.